慢性じん麻疹に対するレミカットの臨床的有用性の検討　特に，症状消失日と投与終了後の持続効果について

DOI

書誌事項

タイトル別名
  • Clinical Evaluation of Remicut(Emedastine Difumarate) in the Treatment of Chronic Urticaria.
  • 特に, 症状消失日と投与終了後の持続効果について

説明

In order to study the effectiveness, safety, and usefulness of remicut® on chronic urticaria, a multicenter open study was conducted. Forty five patients were enrolled in this study and treated with 4 mg/day of emedastine difumarate for two weeks. Results obtained were following; marked improvement in 14 (33%), moderate improvement in 14 (33%), slight improvement in 8 (19%). The final global improvement ratio was 65%. Itching or eruption (wheals and erythema) disappeared within two weeks' administration in 60.5%, 53.5% of the patients, respectively. A clinical adverse reactions, such as sleepiness, were seen in 8 patients and disappeared without symptomatic treatment. Thus, the global utility ratio was 62.2%(28/45).<BR>These results support the efficacy and safety of remicut® in management for choronic urticaria.

収録刊行物

  • 皮膚

    皮膚 38 (1), 104-110, 1996

    日本皮膚科学会大阪地方会

キーワード

詳細情報 詳細情報について

  • CRID
    1390001204798915072
  • NII論文ID
    130004045697
  • DOI
    10.11340/skinresearch1959.38.104
  • ISSN
    1884541X
    00181390
  • 本文言語コード
    ja
  • データソース種別
    • JaLC
    • CiNii Articles
  • 抄録ライセンスフラグ
    使用不可

問題の指摘

ページトップへ